New Oral Agent for Treatment of Anemia in Patient with Chronic Kidney Disease: Prolyl Hydroxylase Inhibitor / 대한내과학회지
Korean Journal of Medicine
; : 11-16, 2019.
Article
em Ko
| WPRIM
| ID: wpr-759923
Biblioteca responsável:
WPRO
ABSTRACT
Hypoxia inducible factor (HIF)-stabilizers are being developed for the renal anemia treatment. This small molecules inhibit prolyl hydroxylase domain (PHD)-containing enzymes, causing HIF activation instead of degradation under the state of normoxia, finally increase production of intrinsic erythropoiesis. Current treatment guidelines suggest that renal anemia should be treated mainly with iron and erythropoiesis stimulating agents (ESAs). But there are several complications and concerns such as hypertension, ESA refractory anemia and increased cardiovascular mortality in using ESAs. Advantages of HIF stabilizers over ESAs are orally available, no dose-up requirement for inflammation. So far new HIF stabilizers showed efficacy and safety in renal anemia treatment. This new therapeutic agent may emerge as a standard treatment option for renal anmia treatment.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Anemia Refratária
/
Mortalidade
/
Eritropoese
/
Insuficiência Renal Crônica
/
Prolil Hidroxilases
/
Hepcidinas
/
Hematínicos
/
Hipertensão
/
Inflamação
/
Anemia
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Ano de publicação:
2019
Tipo de documento:
Article